Padagis (formerly Perrigo’s generic prescription pharmaceutical business) has announced the launch of its generic version of Zomig zolmitriptan nasal spray for the treatment of migraine headaches in patients aged 12 and older. Altaris acquired Padagis from Perrigo in July 2021, and the FDA approved Padagis’ ANDA for the unit dose nasal spray on September 30, 2021.
In addition to the zolmitriptan nasal spray, Padagis markets azelastine, azelastine / fluticasone propionate, olopatadine, sumatriptan, and triamcinolone nasal sprays. Perrigo aquired the azelastine and olopatadine nasal sprays from Impax in 2018 prior to Impax’s merger with Amneal.
Padagis President and CEO Sharon Kochan said, “This first-to-market launch is our second major product launch as an independent organization since our separation from Perrigo in July and highlights our ongoing commitment and capabilities to develop, manufacture and commercialize high quality, high value alternatives in important treatment categories. The Padagis team continues to leverage our unique and specialized manufacturing technologies and development expertise to deliver valuable products to our customers and patients.”
Read the Padagis press release.
